Project Grant R41GM157947
Award Date
4/1/25
Completion Date
3/31/26
Dollars Obligated
$307K
Federal Agency
National Institute of General Medical Sciences
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Institute of General Medical Sciences (NIGMS) awarded Lynntech Inc. a Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to develop software that optimizes the replication of self-amplifying RNA (saRNA) for use in therapeutic and vaccine applications. The $283,304 award, granted on September 19, 2024, aims to leverage machine learning to improve the replicability of saRNA, which can enhance the duration and expression of cargo genes of...
The National Institute of General Medical Sciences (NIGMS) awarded a $300,518 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to E&E Bioclub LLC in Indianapolis, IN. The purpose of this 1-year grant, from Sep 1, 2024 to Aug 31, 2025, is to develop an all-in-one platform for intracellular overproduction of long, single-strand mRNA. This addresses challenges in current mRNA manufacturing approaches, which are constrained by high costs, lack of...
The National Institute of General Medical Sciences (NIGMS) awarded Attogene Corporation, a biotechnology company based in Austin, Texas, a $229,975 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to develop a rapid, portable, and sensitive test for detecting ribonucleases (RNases). The grant supports the company's efforts to create a novel lateral flow assay prototype that can quickly identify RNase contamination, which is critical for ensuring quality...
This $700,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of next-generation RNAi (RNA interference) therapeutics and an in vivo model to evaluate their efficacy and biodistribution. The award aims to establish a pipeline to rapidly test new RNAi-based biological drugs coupled with various delivery platforms, including peptide-based, aptamer-based, and...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $283,805 to Invizyne Technologies, Inc. to develop a cell-free, high-throughput platform to engineer enzymes for biocatalytic "bioclick" reactions. The project aims to establish an in-house cell-free protein synthesis system to rapidly express variant libraries of a prenylation enzyme, and leverage...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $3,111,892 to RNAconnect, Inc. over a period from May 2024 to April 2026. The objective is to develop, optimize, and commercialize UltraMarathonRT, a new reverse transcriptase (RT) enzyme capable of accurately detecting and sequencing RNAs regardless of length or composition. This innovative enzyme is expected to...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research by Chimerna Therapeutics, Inc. to develop a scalable and low-cost method for semi-synthesis of site-specifically labeled circular RNAs. The $302,605 award, granted on February 1, 2025, with a completion date of January 31, 2026, aims to optimize a bacterial strain and expression conditions for...
The National Institute of General Medical Sciences (NIGMS) awarded a $371,606 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Regents of the University of Michigan. The funding will support a research program to advance the understanding and design of RNA therapeutics and their delivery via nanomaterials. Key objectives include: (1) developing an ultrasensitive screening platform to identify RNA cargo and carrier determinants enabling functional in...
This federal Project Grant award for $313,520, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of novel chemical probe technologies to map RNA-protein complexes in live cells. The principal investigator's laboratory is enhancing the RNP-MAP framework to enable 1) transcriptome-wide mapping of multi-protein networks on RNAs, 2) measurement of RNA site-specific occupancy by...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $205,926 to Abbratech Inc. to develop a comprehensive platform for the identification and validation of recombinant antibodies specific to protein isoform splice-junction sites. The key objectives are to validate existing splice-site specific antibodies and generate new ones using an innovative "EpiVolve" phage...